MY153262A - Amino-piperidine derivatives as cetp inhibitors - Google Patents

Amino-piperidine derivatives as cetp inhibitors

Info

Publication number
MY153262A
MY153262A MYPI20090048A MYPI20090048A MY153262A MY 153262 A MY153262 A MY 153262A MY PI20090048 A MYPI20090048 A MY PI20090048A MY PI20090048 A MYPI20090048 A MY PI20090048A MY 153262 A MY153262 A MY 153262A
Authority
MY
Malaysia
Prior art keywords
amino
piperidine derivatives
cetp inhibitors
cetp
compound
Prior art date
Application number
MYPI20090048A
Inventor
Imase Hidetomo
Yasoshima Kayo
Iwaki Yuki
Kawanami Toshio
Miyake Takahiro
Mogi Muneto
Ohmori Osamu
Qin Hongbo
Umemura Ichiro
Yamada Ken
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY153262A publication Critical patent/MY153262A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

THE PRESENT INVENTION PROVIDES A COMPOUND OF FORMULA (I), WHEREIN THE VARIANTS R1, R2, R3, R4, R5, R6, R7 ARE AS DEFINED HEREIN, AND WHEREIN SAID COMPOUND IS AN INHIBITOR OF CETP, AND THUS CAN BE EMPLOYED FOR THE TREATMENT OF A DISORDER OR DISEASE MEDIATED BY CETP OR RESPONSIVE TO THE INHIBITION OF CETP.
MYPI20090048A 2006-07-20 2007-07-18 Amino-piperidine derivatives as cetp inhibitors MY153262A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117541 2006-07-20
US88705807P 2007-01-29 2007-01-29

Publications (1)

Publication Number Publication Date
MY153262A true MY153262A (en) 2015-01-29

Family

ID=37680601

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20090048A MY153262A (en) 2006-07-20 2007-07-18 Amino-piperidine derivatives as cetp inhibitors

Country Status (13)

Country Link
KR (1) KR20120034774A (en)
CN (1) CN101490035B (en)
BR (1) BRPI0714516A2 (en)
DK (1) DK2049517T3 (en)
ES (1) ES2449571T3 (en)
MY (1) MY153262A (en)
NZ (1) NZ573439A (en)
PT (1) PT2049517E (en)
RU (1) RU2442782C2 (en)
SG (1) SG173378A1 (en)
SI (1) SI2049517T1 (en)
UA (1) UA96942C2 (en)
ZA (1) ZA200810008B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112898257B (en) * 2021-03-12 2023-01-24 天津理工大学 Synthetic method of water-soluble coumarin derivative inner salt

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (en) * 1994-03-18 1998-06-26 Sanofi Sa Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
DK2049517T3 (en) 2014-03-03
CN101490035B (en) 2013-02-13
BRPI0714516A2 (en) 2014-07-08
UA96942C2 (en) 2011-12-26
RU2009105763A (en) 2010-08-27
SI2049517T1 (en) 2014-04-30
SG173378A1 (en) 2011-08-29
CN101490035A (en) 2009-07-22
KR20120034774A (en) 2012-04-12
ES2449571T3 (en) 2014-03-20
ZA200810008B (en) 2009-11-25
NZ573439A (en) 2012-02-24
PT2049517E (en) 2014-03-10
RU2442782C2 (en) 2012-02-20

Similar Documents

Publication Publication Date Title
TN2009000012A1 (en) Amino-piperidine derivatives as cetp inhibitors
JO2732B1 (en) Organic Compounds
MX2010006063A (en) 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis.
MX2009006630A (en) 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors.
MX2009003834A (en) Pyrrolydine derivatives as iap inhibitors.
MX2009006481A (en) Organic compounds.
MX2012002752A (en) Heteroaryl compounds as kinase inhibitors.
MA33776B1 (en) Derivatives of arylcarbonyl and non-aryl carbonyl
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
SG171593A1 (en) Inhibitors of c-fms kinase
GEP20115306B (en)
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
GEP20146004B (en) Pyridazinone compounds
ATE542813T1 (en) 6-SUBSTITUTED 2-HETEROCYCLYLAMINOPYRAZINE COMPOUNDS AS CHK-1 INHIBITORS
JO3007B1 (en) Compounds and compositions as protein kinase inhibitors
MX2009005795A (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors.
MX2009009699A (en) Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5- phenylimidazolone compounds as ã¿-secretase inhibitors.
MX2009004822A (en) Phenylpropionamide compounds and the use thereof.
IN2012DN01273A (en)
IL198901A0 (en) Pyrimidine derivatives and multiple myeloma
GEP20146201B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
MX2009004982A (en) Heterocyclic derivatives as cetp inhibitors.
ATE517873T1 (en) 6-OXO-1,6-DIHYDROPYRIMIDINE-2-YLE IN THE TREATMENT OF PROLIFERATIVE DISEASES
MX2009005249A (en) Organic compounds.
DE602007011434D1 (en) 1H-indol-5-yl-piperazin-1-YLMETHANONDERIVATE